The underlying mechanisms for the subsets of self-limiting, intermittent or chronic and deforming arthritis in systemic lupus erythematosus (SLE) are not well understood. We performed a cross-sectional analysis of pro-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8 and TNF-α) and joint status in 47 SLE patients (79% females, age 42 years, disease duration 8.6 years). All cytokines levels were significantly elevated in SLE patients compared with controls, but only IL-2 and IL-8 levels were higher than in patients with rheumatoid arthritis. SLE patients with ongoing synovitis (19%) and joint deformities (11%) had increased erythrocyte sedimentation rate (ESR), IL-6 and anti-dsDNA Ab levels. IL-6 levels correlated with ESR, anti-dsDNA Ab and haemoglobin, but not with C-reactive protein levels. Arthritis constitutes a considerable burden of disease in SLE over time, and joint deformations are associated with longstanding disease and arthritis flare rates. IL-6 is a potential biomarker and therapeutic target in the prevention of joint damage in SLE arthritis.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
2.
EsdaileJMDanoffDRosenthallLGutkowskiA. Deforming arthritis in systemic lupus erythematosus. Ann Rheum Dis1981; 40: 124–126.
3.
EvansJAHastingsDEUrowitzMB. The fixed lupus hand deformity and its surgical correction. J Rheumatol1977; 4: 170–175.
4.
SimonJAGranadosJCabiedesJMoralesJRVarelaJA. Clinical and immunogenetic characterization of Mexican patients with ‘rhupus’. Lupus2002; 11: 287–292.
5.
FernandezAQuintanaGMattesonEL. Lupus arthropathy: historical evolution from deforming arthritis to rhupus. Clin Rheumatol2004; 23: 523–526.
6.
van VugtRMDerksenRHKaterLBijlsmaJW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis1998; 57: 540–544.
7.
OstendorfBSchererASpeckerCModderUSchneiderM. Jaccoud’s arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum2003; 48: 157–165.
8.
DelleSARienteLScireCA. Ultrasound imaging for the rheumatologist. XXIV. Sonographic evaluation of wrist and hand joint and tendon involvement in systemic lupus erythematosus. Clin Exp Rheumatol2009; 27: 897–901.
9.
SaRDGalvaoVLuizFJde AraujoNCD’AlmeidaFSantiagoM. Magnetic resonance imaging of Jaccoud's arthropathy in systemic lupus erythematosus. Joint Bone Spine2010; 77: 241–245.
10.
PastershankSPResnickD. “Hook” erosions in Jaccoud’s arthropathy. J Can Assoc Radiol1980; 31: 174–175.
11.
BallardMMeyerOAdle-BiassetteHGrossinM. Jaccoud’s arthropathy with vasculitis and primary Sjogren’s syndrome. A new entity. Clin Exp Rheumatol2006; 24: S102–S103.
12.
GalvaoVAttaAMSousa AttaML. Profile of autoantibodies in Jaccoud’s arthropathy. Joint Bone Spine2009; 76: 356–360.
13.
NakamuraKTajimaYTakaiO. Generalized laxity of connective tissue as a possible syndrome in systemic lupus erythematosus. Mod Rheumatol2010; 20: 522–527.
14.
TanakaMSuzukiTKatagiriTAsaokaTKiuchiHDohiY. [Jaccoud’s type arthritis in a patient with unclassified connective tissue disease complicated with alveolar cell carcinoma]. Ryumachi1993; 33: 180–185.
15.
AlvesEMMacieiraJCBorbaEChiuchettaFASantiagoMB. Spontaneous tendon rupture in systemic lupus erythematosus: association with Jaccoud’s arthropathy. Lupus2010; 19: 247–254.
16.
Damian-AbregoGNCabiedesJCabralAR. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus2008; 17: 300–304.
17.
Amezcua-GuerraLMSpringallRMarquez-VelascoRGomez-GarciaLVargasABojalilR. Presence of antibodies against cyclic citrullinated peptides in patients with ‘rhupus’: a cross-sectional study. Arthritis Res Ther2006; 8: R144–R144.
18.
ChanMTOwenPDunphyJ. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol2008; 35: 77–83.
19.
SpronkPEter BorgEJKallenbergCG. Patients with systemic lupus erythematosus and Jaccoud’s arthropathy: a clinical subset with an increased C reactive protein response?Ann Rheum Dis1992; 51: 358–361.
20.
BleifeldCJInglisAE. The hand in systemic lupus erythematosus. J Bone Joint Surg Am1974; 56: 1207–1215.
21.
AringerMHoussiauFGordonC. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford)2009; 48: 1451–1454.
22.
AringerMGraningerWBSteinerGSmolenJS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum2004; 50: 3161–3169.
23.
EilertsenGOBecker-MerokANossentJC. The influence of the 1997 updated classification criteria for systemic lupus erythematosus: epidemiology, disease presentation, and patient management. J Rheumatol2009; 36: 552–559.
24.
GladmanDD. Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Curr Opin Rheumatol1994; 6: 487–492.
25.
GladmanDDUrowitzMBGoldsmithCH. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum1997; 40: 809–813.
26.
NikolaisenCFigenschauYNossentJC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol2008; 35: 380–386.
27.
NikolaisenCRekvigOPNossentHC. Rheumatoid factor by laser nephelometry and Waaler–Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis. Scand J Rheumatol2005; 34: 269–276.
28.
PipiliCSfritzeriACholongitasE. Deforming arthropathy in SLE: review in the literature apropos of one case. Rheumatol Int2009; 29: 1219–1221.
29.
LaustrupHVossAGreenAJunkerP. SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus2010; 19: 239–246.
30.
van denBLNossentHRekvigO. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol2006; 25: 347–352.
31.
PetriMSinghSTesfasyoneHMalikA. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol2009; 36: 2476–2480.
32.
Alarcón-SegoviaDAbud-MendozaCDiaz-JouanenE. Deforming arthropathy of the hands in systemic lupus erythematosus. J Rheumatol1988; 15: 65–69.
33.
RichterCMSteinerGSmolenJSIsenbergDA. Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. Br J Rheumatol1998; 37: 421–424.
34.
SantiagoMBGalvaoV. Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature. Medicine (Baltimore)2008; 87: 37–44.
35.
HuaJKirouKLeeCCrowMK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum2006; 54: 1906–1916.
36.
EspositoPBallettaMMProcinoAPostiglioneLMemoliB. Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis. Lupus2009; 18: 1329–1330.
37.
HirohataSKanaiYMitsuoATokanoYHashimotoH. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol2009; 28: 1319–1323.
38.
NishimotoNMiyasakaNYamamotoK. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol2009; 19: 12–19.
39.
IlleiGGShirotaYYarboroCH. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum2010; 62: 542–552.
40.
LinaresLFGomez-ReinoJJCarreiraPEMorillasLIberoI. C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE). Clin Rheumatol1986; 5: 66–69.
41.
VogtBFuhrnrohrBMullerRSheriffA. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity2007; 40: 295–298.
42.
SpronkPEter BorgEJLimburgPCKallenbergCG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?Clin Exp Immunol1992; 90: 106–110.
43.
SjowallCBengtssonAASturfeltGSkoghT. Anti-CRP autoantibody levels correlate with disease activity in systemic lupus erythematosus. Semin Arthritis Rheum2005; 35: 65–65.
44.
MeyerO. Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine2010; 77: 384–389.
45.
MeijerCHuysenVSmeenkRTSwaakAJ. Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus1993; 2: 359–365.
